- Report of Foreign Issuer (6-K)
15 Marzo 2011 - 7:23AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
March 15, 2011
________________
Crucell NV
(Exact
name of registrant as specified in its charter)
P.O.
Box 2048 Archimedesweg 4 2333 CN Leiden The Netherlands
(Address
of principal executive offices)
000-30962
(Commission
File Number)
________________
Indicate by
check mark whether the registrant files or will file annual reports under cover
of Form 20-F or Form 40-F:
Form
20-F [ x ] Form
40-F [ ]
Indicate by
check mark whether the registrant by furnishing the information contained in
this form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [
] No [ x ]
PRESS RELEASE
Crucell Intends to Delist Ordinary Shares on NYSE
Euronext
Leiden, the Netherlands (March 15, 2011)
– Dutch
biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss
Exchange: CRX) today announced that it has obtained the approval of Euronext
Amsterdam N.V. to terminate the listing of its ordinary shares (Ordinary
Shares) on NYSE Euronext in Amsterdam (NYSE Euronext).
The termination of the listing of Ordinary Shares on NYSE
Euronext was approved by Euronext Amsterdam N.V. and will occur on 12 April
2011. The last trading day will be 11 April 2011.
As of the time of delisting from NYSE Euronext, the
following codes will no longer be applicable to Crucell N.V. (Crucell): symbol
“CRXL”: Euronext code NL0000358562, ISIN: NL0000358562.
Crucell intends to delist the Ordinary Shares from the
Swiss Exchange (SIX) simultaneously with the delisting from NYSE Euronext.
As previously announced on 8 March 2011, to effect the
delisting of the American Depositary Shares (ADSs) from the NASDAQ Global
Market Select (NASDAQ), Crucell intends to file a Form 25 with the U.S.
Securities and Exchange Commission (SEC). Crucell intends to file a Form 15F
with the SEC to deregister and terminate its reporting obligations under the
U.S. Securities Exchange Act of 1934, as amended. The filing of the Form 15F
will precede the delisting of the Ordinary Shares from NYSE Euronext and SIX.
Crucell reserves the right to delay or withdraw for any
reason the filing of the Form 25 and Form 15F or the delisting on NYSE Euronext
and/or SIX.
About Crucell
Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange:
CRX) is a global biopharmaceutical company focused on research development,
production and marketing of vaccines, proteins and antibodies that prevent
and/or treat infectious diseases. In 2010 alone, Crucell distributed more than
105 million vaccine doses in more than 100 countries around the world. Crucell
is one of the major suppliers of vaccines to UNICEF and the developing world.
Crucell was the first manufacturer to launch a fully-liquid pentavalent
vaccine. Called Quinvaxem
®
,
this innovative combination vaccine protects against five important childhood
diseases. Over 180 million doses have been sold since its launch in 2006 in
more than 50 GAVI countries. With this innovation, Crucell has become a major
partner in protecting children in developing countries. Other products in
Crucell’s core portfolio include a vaccine against hepatitis B and a virosomeadjuvanted
vaccine against influenza. Crucell also markets travel vaccines, such as an
oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free
hepatitis A vaccine on the market. Crucell has a broad development pipeline,
with several product candidates based on its unique PER.C6
®
production technology.
Crucell licenses its PER.C6
®
technology
and other technologies to the
biopharmaceutical industry. Important partners and
licensees include Johnson & Johnson, DSM Biologics, sanofi-aventis,
Novartis, Pfizer/Wyeth, GSK, CSL and Merck & Co. Crucell is headquartered
in Leiden, the Netherlands, with offices in China, Indonesia, Italy, Korea,
Malaysia, Spain, Sweden, Switzerland, UK, the USA and Vietnam. Crucell employs
over 1300 people. For more information, please visit www.crucell.com.
Forward-looking statements
This press release contains forward-looking statements
that involve inherent risks and uncertainties. We have identified a number of
important factors that may cause actual results to differ materially from those
contained in such forward-looking statements. For information relating to these
factors please refer to our Form 20-F, as filed with the US Securities and
Exchange Commission on April 7, 2010, in the section entitled ‘Risk Factors’
and in our second quarter 2010 financial results, as filed with the Securities
and Exchange Commission on August 17, 2010 in the section entitled ‘Risk
Paragraph’. The Company prepares its financial statements under International
Financial Reporting Standards (IFRS).
For further information please contact:
Oya Yavuz
Vice President Corporate Communications & Investor
Relations
Tel. +31 (0)71 519 7064
ir@crucell.com
www.crucell.com
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.
|
|
(Registrant)
|
|
|
|
(Date)
|
|
Oya Yavuz
Vice
President Corporate Communications
and Investor Relations
|
Crucell NV ADS, Each Representing One Ordinary Share (MM) (NASDAQ:CRXL)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Crucell NV ADS, Each Representing One Ordinary Share (MM) (NASDAQ:CRXL)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024
Real-Time news about Crucell NV ADS, Each Representing One Ordinary Share (MM) (NASDAQ): 0 recent articles
Más de Artículos de Noticias